LIP
ABBV icon

Liontrust Investment Partners’s AbbVie ABBV Stock Holding History

Liontrust Investment Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-70,000
Closed -$9.48M – 201
2021
Q4 		$9.48M Buy
+70,000
New +$8.27M 0.11% 91

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Liontrust Investment Partners's ABBV Position: Q1 2022 in Review

Liontrust Investment Partners sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 70,000 shares — an estimated $9.48M sold.

Liontrust Investment Partners first reported a position in ABBV in Q4 2021 and held it in 1 quarter. The position peaked at $9.48M in Q4 2021. 3,053 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

  • Liontrust Investment Partners reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
  • Liontrust Investment Partners sold 70,000 AbbVie shares in Q1 2022, an estimated $9.48M.
  • Liontrust Investment Partners first reported a position in AbbVie in Q4 2021 and held it in 1 quarter.
  • Liontrust Investment Partners's AbbVie position peaked at $9.48M in Q4 2021.
  • 3,053 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Liontrust Investment Partners's 13F filing for Q1 2022, filed 13 May 2022.